{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:40:22Z","timestamp":1793176822028,"version":"4.5.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.clgc.2023.08.008","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T18:06:49Z","timestamp":1694282809000},"page":"74-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Intermittent Versus Continuous Androgen Deprivation Therapy for Biochemical Progression After Primary Therapy in Hormone-Sensitive Nonmetastatic Prostate Cancer: Comparative Analysis in Terms of CRPC-M0 Progression"],"prefix":"10.1016","volume":"22","author":[{"given":"Stefano","family":"Salciccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Frisenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Tufano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Di Pierro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Bevilacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Rosati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Gobbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Basile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Moriconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianna","family":"Mariotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Forte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pastore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Cattarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Sciarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Gentilucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.clgc.2023.08.008_bib0001","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.21037\/tau-20-1033","article-title":"Oligometastatic prostate cancer: definition and the role of local and systemic therapy: a narrative review","volume":"10","author":"Mahjoub","year":"2021","journal-title":"Transl Androl Urol"},{"issue":"5","key":"10.1016\/j.clgc.2023.08.008_bib0002","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.euf.2016.12.006","article-title":"The natural history and outcome predictors of metastatic castration resistant prostate cancer","volume":"2","author":"van Soest","year":"2016","journal-title":"Eur Urol Focus"},{"issue":"2","key":"10.1016\/j.clgc.2023.08.008_bib0003","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.clgc.2022.10.003","article-title":"Prevalence and natural history of non-metastatic castrate resistant prostate cancer: a population-based analysis","volume":"21","author":"Hird","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"8","key":"10.1016\/j.clgc.2023.08.008_bib0004","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41585-022-00618-w","article-title":"The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer","volume":"19","author":"Wang","year":"2022","journal-title":"Nat Rev Urol"},{"issue":"7","key":"10.1016\/j.clgc.2023.08.008_bib0005","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41585-021-00470-4","article-title":"Treatment and trials in non-metastatic castration-resistant prostate cancer","volume":"18","author":"Lokeshwar","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.clgc.2023.08.008_bib0006","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2023.08.008_bib0007","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2023.08.008_bib0008","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clgc.2023.08.008_bib0009","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.eururo.2013.04.020","article-title":"Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials","volume":"64","author":"Sciarra","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2023.08.008_bib0010","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.critrevonc.2016.01.008","article-title":"Intermittent androgen deprivation in prostate cancer cases with biochemical progression after radical prostatectomy: are we ready to treat?","volume":"99","author":"Cattarino","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"10.1016\/j.clgc.2023.08.008_bib0011","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s003450000155","article-title":"Intermittent androgen deprivation (IAD) in patients with biochemical failure after radical retropubic prostatectomy (RRP) for clinically localized prostate cancer","volume":"18","author":"Sciarra","year":"2000","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2023.08.008_bib0012","unstructured":"European Urological Association Guidelines: prostate cancer. 2021. Available at: https:\/\/uroweb.org\/guidelines\/prostate-cancer\/chapter\/treatment. Accessed April 12, 2021."},{"issue":"8","key":"10.1016\/j.clgc.2023.08.008_bib0013","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s40261-022-01178-y","article-title":"Nonmetastatic castration-resistant prostate cancer: current challenges and trends","volume":"42","author":"Figueiredo","year":"2022","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clgc.2023.08.008_bib0014","doi-asserted-by":"crossref","first-page":"e16052","DOI":"10.1200\/jco.2013.31.15_suppl.e16052","article-title":"International prevalence of nonmetastatic (M0) castration-resistant prostate cancer (CRPC)","volume":"31","author":"Liede","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.08.008_bib0015","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.urology.2016.06.011","article-title":"Predictors of time to metastasis in castration-resistant prostate cancer","volume":"96","author":"Moreira","year":"2016","journal-title":"Urology"},{"issue":"10","key":"10.1016\/j.clgc.2023.08.008_bib0016","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy","volume":"367","author":"Crook","year":"2012","journal-title":"Engl J Med"},{"issue":"3","key":"10.1016\/j.clgc.2023.08.008_bib0017","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11934-015-0481-2","article-title":"The role of intermittent androgen deprivation therapy in the management of biochemically recurrent or metastatic prostate cancer","volume":"16","author":"Jaswal","year":"2015","journal-title":"Curr Urol Rep"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323002021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323002021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:30:23Z","timestamp":1793176223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767323002021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1558767323002021"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2023.08.008","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intermittent Versus Continuous Androgen Deprivation Therapy for Biochemical Progression After Primary Therapy in Hormone-Sensitive Nonmetastatic Prostate Cancer: Comparative Analysis in Terms of CRPC-M0 Progression","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2023.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}